bevacizumab-maly Alymsys
Selected indexed studies
- Assessing Protein Content and Dimer Formation in the Bevacizumab Reference Product and Biosimilar Versions Marketed in Spain. (Pharmaceutics, 2024) [PMID:39771500]
- The Adverse Effects and Use of Bevacizumab in Patients with Glioblastoma: A Systematic Review and Meta-Analysis. (Pharmaceuticals (Basel), 2025) [PMID:40573192]
_Worker-drafted node — pending editorial review._